Trimethoprim-Sulfamethoxazole Treatment for Severe Pertussis in Infants Younger Than 2 months During a Macrolide-Resistant <i>Bordetella pertussis</i> Outbreak: A Case Series
Summary Since 2023, macrolide-resistant Bordetella pertussis (MRBP) has surged worldwide. Six infants aged &lt;2 months completed a 14-day course of trimethoprim-sulfamethoxazole for suspected MRBP infection without significant adverse events. Trimethoprim-sulfamethoxazole may be a tolerable option in infants in MRBP-dominant settings.
Authors
- Toshihiro Matsui (ORCID: https://orcid.org/0000-0001-9324-1089)
- Tatsuki Ikuse (ORCID: https://orcid.org/0000-0002-0417-6797)
- Kensuke Shoji (ORCID: https://orcid.org/0000-0002-7164-0262)
- Shotaro Matsumoto (ORCID: https://orcid.org/0000-0002-4995-8442)
- H Kato (ORCID: https://orcid.org/0000-0003-1055-4405)
- Rinshu Shimabukuro (ORCID: https://orcid.org/0000-0002-3561-5449)
- Masaki Yamada (ORCID: https://orcid.org/0000-0002-3393-6943)
- Chikara Ogimi (ORCID: https://orcid.org/0000-0002-2166-8152)
- Ito Kato
- Nao Otsuka (ORCID: https://orcid.org/0000-0003-3204-2638)
Institutions
- National Institute of Infectious Diseases (JP)
- National Center For Child Health and Development (JP)
Publication Details
- Journal
- Journal of the Pediatric Infectious Diseases Society
- Published
- 2026-06-24
- DOI
- https://doi.org/10.1093/jpids/piag046
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 0.00